Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After Chemotherapy

Next Previous
X
Search
Trial Profile

A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After Chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Acronyms AveNEC

    • Most Recent Events

    • 24 Oct 2023 Results (n=60 from AVENEC study and n=19 from CABOAVENEC study) assessing the effect of anti-PDL1 therapy with avelumab with highly proliferative neuroendocrine tumors from AVENEC and comparing it with interim analysis of 19 progressive NEN G3 pts from CABOAVENEC presented at the 48th European Society for Medical Oncology Congress
    • 24 Feb 2022 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top